ArticleAdvances in therapy2023

Cost-Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China.

Jian Ming et al.PubMed ↗Publisher ↗

No numbers read from the abstract.